Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(22%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
5
56%
Ph phase_3
2
22%
Ph not_applicable
1
11%
Ph phase_4
1
11%

Phase Distribution

0

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
1(11.1%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(4)
Completed(2)
Terminated(1)
Other(2)

Detailed Status

Completed2
unknown2
Not yet recruiting2
Recruiting2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 25 (55.6%)
Phase 32 (22.2%)
Phase 41 (11.1%)
N/A1 (11.1%)

Trials by Status

completed222%
unknown222%
not_yet_recruiting222%
recruiting222%
withdrawn111%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_2

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

NCT06065046
not_yet_recruitingphase_3

Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

NCT05651880
completednot_applicable

Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis

NCT05969730
recruitingphase_4

Effect of JAK Inhibitor on Erosion Healing in RA

NCT05955066
withdrawnphase_3

REVERSE-Long COVID-19 With Baricitinib Study

NCT05858515
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06065046Phase 2

Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

Recruiting
NCT05651880Phase 3

Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior Uveitis

Not Yet Recruiting
NCT05969730Not Applicable

Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis

Completed
NCT05955066Phase 4

Effect of JAK Inhibitor on Erosion Healing in RA

Recruiting
NCT05858515Phase 3

REVERSE-Long COVID-19 With Baricitinib Study

Withdrawn
NCT06662721Phase 2

Baricitinib for Refractory Takayasu Arteritis

Completed
NCT06439615Phase 2

Baricitinib for the Lung Injury Following Spontaneous SAH

Not Yet Recruiting
NCT05914584Phase 2

"Baricitinib for Treating Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype.

Unknown
NCT05686746Phase 2

Use of Baricitenib to Maintain of Remission

Unknown

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9